Informations générales (source: ClinicalTrials.gov)
Multicentric Cohort of HIV Patient With Extrem Profil (CODEX)
Interventional
N/A
ANRS, Emerging Infectious Diseases (Voir sur ClinicalTrials)
février 2012
septembre 2023
19 octobre 2024
A consortium of research teams has studied the immunovirological characteristics of these
patients:
The ANRS CO15 ALT cohort The ANRS CO18 HIV Controller cohort the ANRS EP47 VISCONTI study
Etablissements
| Les établissements d'Île-de-France ayant mis à jour leurs données Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| CHI DE CRETEIL | Isabelle DELACROIX-SZMANIA | 29/03/2024 01:27:32 | Contacter | ||
| HOPITAL NOVO | BLUM | 04/07/2024 11:04:56 | Contacter | ||
| Les établissements d'Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
| HOPITAL FOCH | vendredi 11 mars 2022 | Contact (sur clinicalTrials) | |||
| Les établissements sans correspondance certaine dans le répertoire FINESS dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
| Lambotte - Kremlin Bicetre - France | Contact (sur clinicalTrials) | ||||
Critères
Tous
Inclusion Criteria:
- Patient infected with HIV-1 and not co-infected with HIV-2
- Age ≥ 18 at enrollment
- Able to give written consent
- Covered by French Social Security
- accept the constraints imposed by the study
- without antiretroviral therapy for ALT, HIC and ALT HIC groups and a control of
viral load after antiretroviral treatment interruption in PTC group
ALT group: Documented HIV-1 seropositive for at least 8 years with a CD4 count above
600/mm3 with a rate stable or increasing (positive or zero slope) on at least three
consecutive examinations performed during the last 5 years regardless of the viral load
in the absence of antiretroviral treatment
HIC group: HIV-1 Seropositivity known for at least five years, asymptomatic, with the
last 5 viral loads in HIV-RNA consecutive <400 copies / mL regardless of CD4 count in the
absence of antiretroviral treatment
ALT HIC group: HIV-1 seropositive known for at least 8 years and CD4 cell counts greater
than 600/mm3 with a rate stable or increasing (positive or zero slope) on at least three
consecutive examinations performed during the last 5 years and with the last 5 viral
loads in HIV-RNA consecutive <400 copies / mL in the absence of antiretroviral therapy.
PTC group: Patients with plasma HIV RNA > 2000 copies/mL before initiation of
antiretroviral therapy. Treatment started during the primary infection (as defined by
symptoms associated with seroconversion, as confirmed by a first negative ELISA and/or an
incomplete P24-positive Western blot) or during the chronic phase of infection, and
maintained for at least 12 months in both cases. Control of viral load after
antiretroviral treatment interruption: patients must have at least two available viral
load assays after stopping antiretroviral therapy. All viral loads must be <400 copies/mL
for 12 months or more after stopping antiretroviral therapy, with the possible exception
of one blip (one viral load above 400 copies/mL between two viral loads <400 copies/mL at
least one month apart from the blip; in this case at least three viral load assays will
be required). The last plasma viral load value at the time of inclusion must always be
<400 copies/mL
- Patient infected with HIV-1 and not co-infected with HIV-2
- Age ≥ 18 at enrollment
- Able to give written consent
- Covered by French Social Security
- accept the constraints imposed by the study
- without antiretroviral therapy for ALT, HIC and ALT HIC groups and a control of
viral load after antiretroviral treatment interruption in PTC group
ALT group: Documented HIV-1 seropositive for at least 8 years with a CD4 count above
600/mm3 with a rate stable or increasing (positive or zero slope) on at least three
consecutive examinations performed during the last 5 years regardless of the viral load
in the absence of antiretroviral treatment
HIC group: HIV-1 Seropositivity known for at least five years, asymptomatic, with the
last 5 viral loads in HIV-RNA consecutive <400 copies / mL regardless of CD4 count in the
absence of antiretroviral treatment
ALT HIC group: HIV-1 seropositive known for at least 8 years and CD4 cell counts greater
than 600/mm3 with a rate stable or increasing (positive or zero slope) on at least three
consecutive examinations performed during the last 5 years and with the last 5 viral
loads in HIV-RNA consecutive <400 copies / mL in the absence of antiretroviral therapy.
PTC group: Patients with plasma HIV RNA > 2000 copies/mL before initiation of
antiretroviral therapy. Treatment started during the primary infection (as defined by
symptoms associated with seroconversion, as confirmed by a first negative ELISA and/or an
incomplete P24-positive Western blot) or during the chronic phase of infection, and
maintained for at least 12 months in both cases. Control of viral load after
antiretroviral treatment interruption: patients must have at least two available viral
load assays after stopping antiretroviral therapy. All viral loads must be <400 copies/mL
for 12 months or more after stopping antiretroviral therapy, with the possible exception
of one blip (one viral load above 400 copies/mL between two viral loads <400 copies/mL at
least one month apart from the blip; in this case at least three viral load assays will
be required). The last plasma viral load value at the time of inclusion must always be
<400 copies/mL
Under protection(saving) of justice